Tvardi Therapeutics

Forecast & Rating9 analysts currently cover Tvardi Therapeutics, with about 77.8% giving a positive rating — meaning they expect the stock to rise. The average price target is $9.75, about 288.4% upside from the current price of $2.51. Price targets range from $3.00 to $15.00 — a wide spread, showing clear disagreement over just how much Tvardi Therapeutics can rise. For you, this means most professionals who study Tvardi Therapeutics closely still see room for the stock to rise. Data as of Jul 8, 2026; for reference only and not investment advice.